Health Discovery (HDVY) 10-K 31 Mar 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Mar. 31, 2015	Jun. 30, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	HEALTH DISCOVERY CORP
Entity Central Index Key	1141788
Trading Symbol	hdvy
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Current Fiscal Year End Date	-19
Entity Filer Category	Smaller Reporting Company
Entity Well-Known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding		261,384,810
Entity Public Float			$7,576,719
Document Type	10-K
Document Period End Date	31-Dec-14
Amendment Flag	FALSE
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY

Balance_Sheets

Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current Assets
Cash	$7,642	$71,991
Accounts Receivable	1,969	80
Investment in Available For Sale Securities (Note J)	362,373	724,000
Total Current Assets	371,984	796,071
Equipment, Less Accumulated Depreciation of $59,765 and $55,133 at December 31, 2014 and December 31, 2013, respectively	1,120	5,752
Other Assets
Patents, Less Accumulated Amortization of $2,782,009 and $2,519,290 at December 31, 2014 and December 31, 2013, respectively	1,203,785	1,466,504
Total Assets	1,576,889	2,268,327
Current Liabilities
Accounts Payable - Trade	239,910	326,267
Accrued Liabilities		2,500
Dividends Payable	373,346	308,724
Deferred Revenue	43,388	1,024,988
Total Current Liabilities	656,644	1,662,479
Long Term Liabilities
Deferred Revenue	148,240	191,628
Total Liabilities	804,884	1,854,107
Stockholders' Equity
Common Stock, No Par Value, 300,000,000 Shares Authorized 261,384,810 Shares Issued and Outstanding December 31, 2014 252,557,310 Shares Issued and Outstanding December 31,2013	27,055,938	26,368,892
Accumulated Deficit	-26,615,933	-26,792,574
Total Stockholders' Equity	772,005	414,220
Total Liabilities and Stockholders' Equity	1,576,889	2,268,327
Series B Preferred Stock Convertible
Current Liabilities
Dividends Payable	373,346	308,724
Stockholders' Equity
Preferred stock, convertible		677,902
Series C Preferred Stock Convertible
Stockholders' Equity
Preferred stock, convertible	$332,000	$160,000

Balance_Sheets_Parentheticals

Balance Sheets (Parentheticals) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Accumulated depreciation on equipment (in dollars)	59,765	55,133
Accumulated amortization on patents (in dollars)	2,782,009	2,519,290
Common Stock, no par value (in dollars per share)
Common Stock, shares authorized	300,000,000	300,000,000
Common Stock, shares issued	261,384,810	252,557,310
Common Stock, shares outstanding	261,384,810	252,557,310
Series B Preferred Stock Convertible
Preferred Stock, shares authorized	20,625,000	20,625,000
Preferred Stock, shares issued		8,827,500
Preferred Stock, shares outstanding		8,827,500
Series C Preferred Stock Convertible
Preferred Stock, shares authorized	20,000,000	20,000,000
Preferred Stock, shares issued	6,640,000	2,000,000
Preferred Stock, shares outstanding	6,640,000	2,000,000

Statements_of_Operations

Statements of Operations (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Revenues:
Licensing & Development	$1,032,127	$1,053,607
Operating Expenses:
Amortization	262,719	262,719
Professional and Consulting Fees	161,600	714,701
Legal Fees	58,950	269,961
Research & Development Fees	99,200	115,934
Compensation	249,475	524,144
Other General and Administrative Expenses	161,735	418,221
Total Operating Expenses	993,679	2,305,680
Income (Loss) From Operations	38,448	-1,252,073
Other Income (Expense)
Unrealized Loss on Available for Sale Securities (Note J)	-199,894	-288,600
Realized Gain on Available for Sale Securities (Note J)	338,087	815,753
Settlement Expense (Note G)		-50,000
Total Other Income	138,193	477,153
Net Income (Loss)	176,641	-774,920
Preferred Stock Dividends	64,622	137,256
Net Income (Loss) Attributable to Common Stockholders	$112,019	($912,176)
Weighted Average Outstanding Shares - basic and diluted (in shares)	253,292,935	235,494,741
Earnings (Loss) Per Share (basic and diluted) (in dollars per share)	$0.00	($0.00)

Statements_of_Changes_in_Stock

Statements of Changes in Stockholders' Equity (USD $)	Preferred Shares	Preferred Shares	Common Shares	Accumulated Deficit	Total
	Preferred Shares C	Preferred Shares B
Balance at Dec. 31, 2012		$1,307,628	$25,445,813	($26,017,654)	$735,787
Balance (in shares) at Dec. 31, 2012		17,340,175	233,773,144
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Series C Preferred Stock Issued	160,000				160,000
Series C Preferred Stock Issued (in shares)	2,000,000
Stock-based Compensation Expense for Directors and Consultants			124,889		124,889
Share-based Compensation Expense for Employees			30,855		30,855
Series B Preferred Stock Dividend Paid with Common Stock			274,865		274,865
Series B Preferred Stock Dividend Paid with Common Stock (in shares)			10,271,491
Series B Preferred Stock Annual Dividend			-137,256		-137,256
Series B Preferred Stock Exchanged for Common Stock		-629,726	629,726
Series B Preferred Stock Exchanged for Common Stock (in shares)		-8,512,675	8,512,675
Net Income (Loss)				-774,920	-774,920
Balance at Dec. 31, 2013	160,000	677,902	26,368,892	-26,792,574	414,220
Balance (in shares) at Dec. 31, 2013	2,000,000	8,827,500	252,557,310
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Series C Preferred Stock Issued	172,000				172,000
Series C Preferred Stock Issued (in shares)	4,640,000
Stock-based Compensation Expense for Directors and Consultants			58,416		58,416
Share-based Compensation Expense for Employees			15,350		15,350
Series B Preferred Stock Dividend Paid with Common Stock
Series B Preferred Stock Dividend Paid with Common Stock (in shares)
Series B Preferred Stock Annual Dividend			-64,622		-64,622
Series B Preferred Stock Exchanged for Common Stock		-677,902	677,902
Series B Preferred Stock Exchanged for Common Stock (in shares)		-8,827,500	8,827,500
Net Income (Loss)				176,641	176,641
Balance at Dec. 31, 2014	$332,000		$27,055,938	($26,615,933)	$772,005
Balance (in shares) at Dec. 31, 2014	6,640,000		261,384,810

Statements_of_Cash_Flows

Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Cash Flows From Operating Activities
Net Income (Loss)	$176,641	($774,920)
Adjustments to Reconcile Net Income (Loss) to Net Cash Used for Operating Activities:
Stock-based Compensation for Employees	15,350	30,855
Stock-based Compensation for Directors and Consultants	58,416	124,889
Realized Gain on Investments in Available for Sale Securities Measured in Accordance with the Fair Value Option (Note J)	-338,087	-815,753
Unrealized Loss on Investments in Available for Sale Securities Measured in Accordance with the Fair Value Option (Note J)	199,894	288,600
Depreciation and Amortization	267,351	270,633
(Decrease) Increase in Accounts Receivable	-1,889	10
Decrease in Deferred Revenue	-1,024,988	-1,024,988
(Decrease) Increase in Accounts Payable - Trade	-86,357	186,476
Decrease in Accrued Liabilities	-2,500	-53,000
Net Cash Used for Operating Activities	-736,169	-1,767,198
Cash Flows From Investing Activities:
Proceeds from Sale of Available for Sale Securities (Note J)	499,820	1,519,313
Purchase of Equipment		-2,336
Net Cash Provided by Investing Activities	499,820	1,516,977
Cash Flows From Financing Activities:
Proceeds from Series C Preferred Stock Issuance	172,000	160,000
Dividends Paid	0	-9,212
Net Cash Provided by Financing Activities	172,000	150,788
Net Decrease in Cash	-64,349	-99,433
Cash, at Beginning of Period	71,991	171,424
Cash, at End of Period	$7,642	$71,991

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Note A - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	DESCRIPTION OF BUSINESS
	Health Discovery Corporation (the “Company”) is a biotechnology-oriented company that has acquired patents and has patent pending applications for certain machine learning tools, primarily pattern recognition techniques using advanced mathematical algorithms to analyze large amounts of data thereby uncovering patterns that might otherwise be undetectable.  Such machine learning tools are currently in use for diagnostics and drug discovery, but are also marketed for other applications.  The Company licenses the use of its patent protected technology and may provide services to develop specific learning tools under development agreements or to sell to third parties.
	USE OF ESTIMATES
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period.  Accordingly, actual results could differ from those estimates.  Significant estimates that are particularly susceptible to change in the near-term include the valuation of share-based compensation and consideration for services and the recoverability of the patents.
	REVENUE RECOGNITION
	Revenue is generated through the sale or license of patented technology and processes and from services provided through development agreements.  These arrangements are generally governed by contracts that dictate responsibilities and payment terms.  The Company recognizes revenues as they are earned over the duration of a license agreement or upon the sale of any owned patent once all contractual obligations have been fulfilled.  If a license agreement has an undetermined or unlimited life, the revenue is recognized over the remaining expected life of the patents. Revenue is recognized under development agreements in the period the services are performed.
	CASH
	Cash and cash equivalents include cash and funds invested in money market accounts with financial institutions.
	ACCOUNTS RECEIVABLE
	Trade accounts receivable for licensing fees and development services are recorded at net contract value based upon the written agreement with the customer. In certain cases, accounts receivable may include royalties receivable from customers based upon those customers estimated sales of the products or diagnostic tests containing patented processes and technologies. The Company considers amounts past due based on the related terms of the agreement and reviews its exposure to amounts receivable based upon collection history and specific customer credit analysis.  The Company provides an allowance for doubtful amounts if collectability is no longer reasonably assured.  As of December 31, 2014 and 2013, all amounts receivable are considered fully collectable and no allowance for doubtful accounts was recorded.
	EQUIPMENT
	Equipment, which consists of office furniture, computer equipment, and leasehold improvements, are stated at cost. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which range from 3 to 10 years. Leasehold improvements are amortized using the straight-line method over the estimated useful lives of the assets or the term of the lease, whichever is shorter.
	PATENTS
	Initial costs paid to purchase patents are capitalized and amortized using the straight line method over the remaining life of the patent. The Company capitalizes the external costs and filing fees associated with obtaining patents on its new discoveries and amortizes these costs using the straight-line method over the shorter of the legal life of the patent or its economic life, generally 17 years, beginning on the date the patent is issued.  Annual patent maintenance costs and annual license and renewal registration fees are expensed as period costs. If the applied for patents are abandoned or are not issued, the Company will expense the capitalized costs to date in the period of abandonment or earlier if abandonment appears probable.  The carrying value of patents is reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. As of December 31, 2014, the Company does not believe there has been any impairment of its patents.
	INVESTMENTS
	The Company uses the equity method to account for its equity investments in ventures for which it has 50% or less ownership and the ability to exercise significant influence over operating and financial policies, but does not control. The Company uses the cost method to account for its investments in companies that it does not control and for which it does not have the ability to exercise significant influence over operating and financial policies.
	INCOME TAXES
	The Company accounts for income taxes using the asset and liability method. Deferred tax assets and liabilities are recognized for future tax benefits and expenses or consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income for the years in which those temporary differences are expected to be recovered or settled.
	In the event the future tax consequences of differences between the financial reporting bases and tax bases of the Company’s assets and liabilities result in deferred tax assets, an evaluation is made of the probability of being able to realize the future benefits indicated by such assets is made. A valuation allowance is provided for the portion of the deferred tax asset when it is more likely than not that some portion or all of the deferred tax asset will not be realized. In assessing the probability of realizing the deferred tax assets, management considers the scheduled reversals of deferred tax liabilities, projected future taxable income, and tax planning strategies.
	STOCK-BASED COMPENSATION
	Stock-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the requisite service period.
	Valuation and Amortization Method – The fair value awards of stock that do not contain a market condition target are estimated on the grant date using the Black-Scholes option-pricing model. The fair value of options that contain a market condition, such as a specified hurdle price, is estimated on the grant date using a probability weighted fair value model similar to a lattice valuation model.  Both the Black-Scholes and the probability weighted valuation models require assumptions and estimates of expected volatility, expected life, expected dividend yield and expected risk-free interest rates.
	Expected Term – The expected term of the award represents the period that the Company’s stock-based awards are expected to be outstanding and was determined based on historical experience, giving consideration to the contractual terms of the stock-based awards, vesting schedules, and forfeitures due to departure prior to the end of the vesting schedule.
	Expected Volatility – Volatility is a measure of the amounts by which a financial variable such as stock price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. The Company uses the historical volatility, employing a prior period equivalent to the expected term to estimate expected volatility.
	Risk-Free Interest Rate – The Company bases the risk-free interest rate used in the Black-Scholes valuation method on the implied yield currently available on U.S. Treasury zero-coupon issues with a remaining term equivalent to the expected term of a stock award.
	RESEARCH AND DEVELOPMENT EXPENSE
	The Company’s research and development costs are expensed as incurred and consist of expenses paid to consultants and external laboratories and related primarily to the costs of co-development studies, clinical trials, and projects undertaken. The R&D costs were $99,200 in 2014 and $115,934 in 2013.
	FAIR VALUE OF FINANCIAL INSTRUMENTS
	The Company’s financial instruments consist of cash, available for sale securities, accounts receivable, accounts payable and accrued expenses.  The Company considers the carrying values of its financial instruments in the financial statements to approximate their fair value due to the short-term nature of such items. Refer to Note J for discussion regarding the valuation of the Company’s investment in available for sale securities.
	NET INCOME (LOSS) PER SHARE
	Basic Earnings Per Share (“EPS”) includes no dilution and is computed by dividing income or loss available to common stockholders by the weighted average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution of securities that could share in the earnings or losses of the entity.
	Due to the net loss for the twelve-month period ended December 31, 2013, the calculation of diluted per share amounts would create an anti-dilutive result and therefore are not presented in the following table. Potentially dilutive shares at December 31, 2013, include options and warrants outstanding of 13,500,000.
	The following is an analysis of the basic and diluted earnings per common share computations for the year ended December 31, 2014:
		Year ended
		31-Dec-14
	Basic:
	Net income attributable to common stockholders	$	112,019
	Basic weighted average common shares outstanding		253,292,935
	Basic earnings per common share	$	0.0004
	Diluted:
	Net income attributable to common stockholders	$	112,019
	Basic weighted average common shares outstanding		253,292,935
	Effect of dilutive securities:
	Conversion of options and warrants		-
	Conversion of preferred shares to common shares		6,640,000
	Diluted weighted average common shares outstanding		259,932,935
	Diluted earnings per common share	$	0.0004
	During the twelve-month period ended December 31, 2014, 19,390,000 outstanding stock options and warrants were not included in the computation of diluted earnings per common share because to do so would have an antidilutive effect. Please refer to Note H regarding detail for outstanding stock options.
	CONCENTRATIONS OF CREDIT RISK
	The Company maintains its cash balances at financial institutions that are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000 per account.  From time-to-time, the Company’s cash balances exceed the amount insured by the FDIC.  Management believes the risk of loss of cash balances in excess of the insured limit to be low.
	RECENT ACCOUNTING PRONOUNCEMENTS
	In February 2013, the FASB issued an amendment, which requires disclosure of amounts reclassified out of accumulated other comprehensive income by component. In addition, an entity is required to present either on the face of the statement of operations or in the notes, significant amounts reclassified out of accumulated other comprehensive income by the respective line items of net income but only if the amount reclassified is required to be reclassified to net income in its entirety in the same reporting period. For amounts not reclassified in their entirety to net income, an entity is required to cross-reference to other disclosures that provide additional detail about those amounts. This guidance is effective prospectively for annual and interim periods beginning after December 15, 2012. The adoption of this guidance did not have a material impact on our financial results.

DEFERRED_REVENUE

DEFERRED REVENUE	12 Months Ended
	Dec. 31, 2014
Deferred Revenue Disclosure [Abstract]
DEFERRED REVENUE	Note B – DEFERRED REVENUE
	Deferred revenue represents the unearned portion of payments received in advance for licensing or service agreements.
	The Company received $2,944,800 as a part of the NeoGenomics license agreement in January 2012. Deferred revenue of $2,944,800 was recorded and recognized as income over the three years of the term of the license agreement.
	The Company had total unearned revenue of $191,628 as of December 31, 2014. The long-term portion of unearned revenue represents the remaining term of the agreements or the remaining lives of the underlying patents, as appropriate, and ranges from one to seven years.
	The expected future annual recognition of revenue is as follows:
	2015	$	43,388
	2016		43,388
	2017		43,388
	2018		43,388
	2019		18,076
	Total expected future annual amortization	$	191,628

PATENTS

PATENTS	12 Months Ended
	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
PATENTS	Note C – PATENTS
	The Company has acquired a group of patents related to biotechnology and certain machine learning tools used for diagnostic and drug discovery.
	The cost and accumulated amortization as of December 31, 2014 and 2013 are as follows:
		2014			2013
	Cost of Patents	$	3,985,794		$	3,985,794
	Accumulated Amortization		(2,782,009	)		(2,519,290	)
	Patents, Net of Amortization	$	1,203,785		$	1,466,504
	Amortization charged to operations for each of the years ended December 31, 2014 and 2013 was $262,719.  The weighted average remaining amortization period for patents at December 31, 2014 is 4.50 years.  Estimated amortization expense for the next four years is $260,603 per year.

INVESTMENTS

INVESTMENTS	12 Months Ended
	Dec. 31, 2014
Investments, Debt and Equity Securities [Abstract]
INVESTMENTS	Note D – INVESTMENTS
	On March 27, 2007, the Company and an investment partner formed SVM Capital, LLC (“SVM Capital) as an equity investment for purposes of utilizing SVM as a quantitative investment management technique.  The Company owns 45% of the membership interest and has significant influence with the operation of the entity but does not have control over the entity. The Company does not have any obligation to fund or provide support to SVM Capital.  Accordingly, the investment is accounted for using the equity method of accounting.  The Company’s initial investment was $5,000 and the license to use the SVM technology applied to financial markets.  The carrying value of this investment was zero as of December 31, 2014 and 2013.
	In August 2008, pursuant to a license agreement, as amended, we contributed a license to Smart Personalized Medicine, LLC (“SPM”) in return for a 20% equity interest.  SPM is a company founded by a former director to develop a breast cancer prognostic test using our SVM technology in collaboration with a prominent cancer research hospital. The only activity for this entity was the Quest license and development agreements of 2010 for which there was an allocation of 50% to the Company and 50% to the other partner. The Company does not have any contractual obligation to provide any funds to this venture. The net value of the investment was zero as of December 31, 2014 and 2013. The Company does not anticipate the relationship with SPM will generate any revenue.

LICENSE_FEES_EXPENSE_LUCENT_AG

LICENSE FEES EXPENSE - LUCENT AGREEMENT	12 Months Ended
	Dec. 31, 2014
License Agreement [Abstract]
LICENSE FEES EXPENSE - LUCENT AGREEMENT	Note E – LICENSE FEES EXPENSE - LUCENT AGREEMENT
	Effective September 26, 2004, the Company was assigned a patent license agreement with Lucent Technologies GRL Corporation (“Lucent”).  The patent license agreement was associated with the patents acquired July 30, 2004. The Company agreed to pay royalty fees to Lucent in the amount of the greater of an annual fee of $10,000 or at the rate of five percent (5%) on each licensed product which is sold, leased, or put into use by the Company, until cumulative royalties equal $40,000 and at the rate of one percent (1%) subsequently.  The license granted will continue for the entire unexpired term of Lucent’s patents.  During 2014, the Company paid $6,095 in royalty fees to Lucent compared to $10,536 paid during 2013. The Lucent patents expired in July 2014, and therefore the license agreement with Lucent expired.  The Company is no longer required to make royalty payments to Lucent.

INCOME_TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
INCOME TAXES	Note F – INCOME TAXES
	The Company has incurred net losses since inception, and we have determined that it is more likely than not we will be unable to benefit in the future from the accumulated net operating loss.  Consequently, we have not recorded any U.S. federal or state income tax expense or benefit.  We have not recorded income tax expense or benefit for the fiscal years ending December 31, 2014 or 2013.
	The following items comprise the Company’s net deferred tax assets (liabilities) as of December 31, 2014 and 2013:
		2014			2013
	Deferred tax assets:
	Net operating losses	$	7,877,660		$	7,682,814
	Deferred revenue		65,154			413,649
	Charitable contributions		-			510
	Depreciation and amortization		-			-
	Stock compensation		55,991			54,655
	Deferred tax asset		7,998,805			8,151,628
	Deferred tax liabilities:
	Depreciation and amortization		(4,007	)		(4,007	)
	Unrealized gain		(80,956	)		(148,920	)
	Deferred tax liability		(84,963	)		(152,927	)
	Net deferred tax asset		7,913,842			7,998,701
	Less valuation allowance		(7,913,842	)		(7,998,701	)
	Net deferred taxes	$	-		$	-
	For the year ended December 31, 2014, a decrease in the valuation allowance of $84,859 has been recorded for the deferred tax asset, as management has determined that it is more likely than not that the deferred tax asset will not be realized.
	Total income tax expense (benefit) differed from the amounts computed by applying the U.S. Federal statutory tax rates to pre-tax loss for the fiscal years ending December 31, 2014 and 2013, as follows:
		2014			2013
	Total expense (benefit) computed by:
	Applying the U.S. Federal statutory rate		(34	)%		(34	)%
	State income taxes, net of federal tax benefit		(3	)%		(3	)%
	Valuation allowance		37	%		37	%
	Effective tax rate		-			-
	The Company has unused net operating loss carry-forwards of approximately $23.2 million that are available to offset future income taxes payable. The net operating losses will begin to expire in 2020.
	Based in its evaluation of tax positions, the Company has concluded that there are no significant uncertain tax positions requiring recognition in its financial statements.  The Company’s evaluation was performed for all tax years, which remain subject to examination and adjustment, by major tax jurisdictions as of December 31, 2014. The Company is generally no longer subject to U.S. federal, state, and local, or non-US income tax examinations for the years before 2011.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2014
Legal Matters and Commitment [Abstract]
COMMITMENTS AND CONTINGENCIES	Note G – COMMITMENTS AND CONTINGENCIES
	Operating Lease
	We do not own any real property.  We lease 350 square feet of office space in Atlanta, Georgia, pursuant to a month-to-month lease dated April 1, 2013. We currently pay base rent in the amount of $600 per month. Our principal executive office is well maintained and is suitable for the business conducted in this location.
	Settlements
	The previous Board of Directors negotiated a settlement agreement in July 2013 with Stephen Barnhill, the former Chairman and Chief Executive Officer of the Company.  Under the terms of the Settlement Agreement, (i) the Company paid $50,000 to, or for the benefit of, Mr. Barnhill and (ii) Mr. Barnhill executed a general release in favor of the Company, subject to any indemnification rights that Mr. Barnhill may have under any agreement, law, or insurance policy maintained by the Company. As a result, the Company recognized a settlement expense of $50,000 in 2013.
	Legal Issues
	On July 17, 2013, the Company received a Civil Investigative Demand (the “Demand”) from the Federal Trade Commission of the United States of America (the “FTC”) relating to the Company’s MelApp software application. In the Demand, the FTC has requested information relating to potentially unfair or deceptive acts or practices related to (i) false advertising and (ii) consumer privacy and data security, in violation of Trade Commission Act, 15 U.S.C. Sections 45 and 42.
	On February 23, 2015, the FTC notified the Company of its approval, by a vote of 4-1, to accept an Agreement Containing Consent Order (“Agreement”). This Agreement is for settlement purposes only. The Company neither admits nor denies any of the allegations, except as specifically stated in the Agreement. The Company believes the effort to contest this matter with the FTC would require funds greater than the Company has at its disposal.
	The Agreement will, among other things, bar the Company from claiming that any device detects or diagnoses melanoma or its risk factors, or increases users’ chances of early detection, unless the representation is not misleading and supported by competent and reliable scientific evidence in the form of human clinical testing of the device. The Agreement also prohibits the Company from making any other misleading or unsubstantiated claims about a device’s health benefits or efficacy, unless the representation is not misleading and supported by competent and reliable scientific evidence in the form of human clinical testing of the device. Finally, the Company must pay $17,963 to the FTC.
	The Company is subject to various claims primarily arising in the normal course of business.  Although the outcome of these matters cannot be determined, the Company does not believe it is probable that any such claims will result in material costs and expenses.

STOCK_COMPENSATION_AND_EQUITY_

STOCK COMPENSATION AND EQUITY BASED PAYMENTS	12 Months Ended
	Dec. 31, 2014
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]
STOCK COMPENSATION AND EQUITY BASED PAYMENTS	Note H – STOCK COMPENSATION AND EQUITY BASED PAYMENTS
	Information about options and warrants outstanding for 2014 and 2013 is summarized below:
	Number of Warrants and Options Issued	2014			Weighted Average		2013			Weighted Average
					Exercise Price					Exercise Price
	Outstanding beginning of year		13,500,000		$	0.05		12,250,000		$	0.1
	Granted		6,640,000		$	0.03		17,750,000		$	0.04
	Exercised		-		$	-		-		$	-
	Forfeited		-		$	-		(8,500,000	)	$	0.12
	Expired un-exercised		(750,000	)	$	0.08		(8,000,000	)	$	0.08
	Outstanding end of the year		19,390,000		$	0.034		13,500,000		$	0.05
	Exercisable December 31		13,723,335		$	0.034		4,750,000		$	0.04
	31-Dec-14
	Exercise Prices	Number			Weighted-		Number			Weighted
		Outstanding			Average		Exercisable			Average
					Remaining					Remaining
					Contractual					Contractual Life
					Life (years)					(years) of
										Exercisable
										Warrants
	$0.03		3,000,000			8.5		1,000,000			8.5
	$0.03		6,640,000			9.5		6,640,000			9.5
	$0.04		7,750,000			8.75		4,083,335			8.75
	$0.04		1,000,000			3		1,000,000			3
	$0.05		1,000,000			3		1,000,000			3
	Total		19,390,000					13,723,335
	As of December 31, 2014, there was $120,175 of unrecognized cost related to stock option and warrant grants.  The cost is to be recognized over the remaining vesting periods that average approximately 1.5 years.  The weighted average remaining life of all outstanding warrants and options at December 31, 2014 are 8.5 years.  The aggregate intrinsic value of all options and warrants outstanding and exercisable as of December 31, 2014 was zero, based on the market closing price of $0.02 on December 31, 2014, less exercise prices.
	While no options were issued in 2014, the Company recognizes the cost of options awarded in earlier years over the vesting period.  As a result, stock-based expense included in the 2014 net income consisted of $73,766. Specifically, director option expenses were $33,199 and option expenses related to employees and consultants were $40,567.
	The following table reflects stock-based compensation and expense recorded in 2014 and 2013:
		2014			2013
	Director and consultant option expenses	$	58,416		$	124,889
	Employee option expenses		15,350			30,855
	Total stock compensation expenses	$	73,766		$	155,744
	In connection with their election to the Board of Directors, on July 25, 2013, the Company granted to Mr. Henry Kaplan, Mr. Kevin Kowbel, and Mr. Eric Winger each an option to purchase 1,500,000 shares of the Company’s common stock. Upon his appointment to Interim Chief Executive Officer, Mr. Kowbel returned his options back to the Company. As a result, only the options for Messrs. Kaplan and Winger vest 250,000 shares every six months, have an exercise price of $0.027, and expire on July 25, 2023.  The fair value of each option granted is $0.020 and was estimated on the date of grant using the Black-Scholes pricing model with the following assumptions: dividend yield at 0%, risk-free interest rate of 1.91%, an expected life of 5 years, and volatility of 98%.  The aggregate computed value of these options is $60,124, and this amount will be charged as an expense over the three-year vesting period. There is no expense related to Mr. Kowbel as he returned all of the options granted to him back to the Company.
	In connection with his appointment to the Board of Directors in July 2013, on October 21, 2013, Mr. William F. Quirk, Jr. was granted an option to purchase 1,500,000 shares of the Company’s common stock. This option grant is consistent with what has been granted to other board members. The options vest 250,000 shares every six months, have an exercise price of $0.036, and expire on October 21, 2023.
	Also, on October 21, 2013, the Company granted options to purchase 6,000,000 shares of the Company’s common stock to a group of employees and consultants in recognition of their efforts to lower the Company’s monthly expenditures and compensation and their continuing contributions to the Company.  The options vest over a three-year period, have an exercise price of $.036, and expire on October 21, 2023. Within the group of 6,000,000 options, the Company’s Vice President, Mark A. Moore, Ph.D., received an option to purchase 1,000,000 shares of the Company’s common stock and the Company’s Senior Vice President, Hong Zhang, Ph.D., received an option to purchase 750,000 shares of the Company’s common stock.  The non-cash charge of $203,931 for the fair value of these options will be recognized as an expense over the three-year vesting period.

STOCKHOLDERS_EQUITY

STOCKHOLDERS' EQUITY	12 Months Ended
	Dec. 31, 2014
Stockholders Equity Note [Abstract]
STOCKHOLDERS' EQUITY	Note I - STOCKHOLDERS’ EQUITY
	Series B Preferred Stock
	During the first quarter of 2009, the Board of Directors authorized the designation of Series B Preferred Stock. The number of shares originally constituting the Series B Preferred Stock was 13,750,000; however, during the fourth quarter of 2009 the Board of Directors authorized the increase in the number of shares constituting the Series B Preferred Stock to 20,625,000. The Company sold to individual investors a total of 19,402,675 shares of Series B Preferred Stock for $1,490,015, net of associated expenses, in 2009.  The Series B Preferred Stock has not been registered under either federal or state securities laws and must be held until a registration statement covering such securities is declared effective by the Securities and Exchange Commission or an applicable exemption applies.
	The Series B Preferred Stock was converted into Common Stock of the Company in the fourth quarter of 2014, which was the fifth anniversary of the date of issuance as outlined in the original purchase agreement.
	The Series B Preferred Stock accrued dividends at the rate of 10% of the Series B Original Issue Price per year, and was to be satisfied by the fifth anniversary of the issuance of such shares of the Series B Preferred Stock (the “Original Issue Date”) by the Company’s issuance of the number of shares of Common Stock equal to such accrued dividends divided by the average closing price of the Company’s Common Stock as reported on the Over-the-Counter-Bulletin Board or other exchange on which the Company’s Common Stock trades during the prior ten business days or by the payment of cash, as the Company may determine in its sole discretion.
	No dividend payment will be made if, after the payment of such dividend, the Company would not be able to pay its debts as they become due in the usual course of business, or if the Company’s total assets would be less than the sum of its total liabilities plus the amount that would be needed, if the Company were to be dissolved, to satisfy the preferential rights upon the dissolution to shareholders whose preferential rights are superior to those receiving the dividend.
	Dividends have been accrued for the Series B Preferred Stock in the amount of $373,346 as of December 31, 2014 and $308,724 as of December 31, 2013. The Company has given the Series B holders the choice of either (1) Common Stock for the amount of the dividend accrued based upon the price of $0.05 per share or (2) to defer payment of the dividend in cash until the Company is able to pay, at the sole discretion of the Company.  At the period ended December 31, 2014, the entire accrued dividend is recorded as a current liability in the amount of $373,346.
	Series C Preferred Stock
	In the fourth quarter of 2013, the Board of Directors authorized the issuance of Series C Preferred Shares in private placement transactions. As of December 31, 2013 2,000,000 shares had been issued and the Company received net proceeds of $160,000. As of December 31, 2014 the Company had issued a total of 6,640,000 preferred shares and received total net proceeds of $332,000. The Series C Preferred Shares are accompanied by $0.03 warrants and $0.03 contingency warrants. The contingency warrants will be issued only if the company has not attained profitability by the end of the first quarter 2016. The holders must exercise fifty percent of the warrants if the market price for the Company’s common stock is $0.20 for a period of thirty consecutive calendar days.  The holders must also exercise fifty percent of the warrants if the market price for the Company’s common stock is $0.30 for a period of thirty consecutive calendar days.  The warrants were valued at $0.025 each using the Black Scholes Method.
	This funding is anti-dilutive because the purchase price is significantly higher than the current 180-day average share price. The Series C Preferred Stock has not been registered under either federal or state securities laws and must be held until a registration statement covering such securities is declared effective by the Securities and Exchange Commission or an applicable exemption applies.
	The Series C Preferred Stock may be converted into Common Stock of the Company at the option of the holder, without the payment of additional consideration by the holder, so long as the Company has a sufficient number of authorized shares to allow for the exercise of all of its outstanding warrants and options. The Shares of Series C Preferred Stock must be converted into Common Stock of the Company either by the demand by the shareholder or at the fifth anniversary of the date of issuance. If the Company were to be dissolved, the Series C Preferred Stock receives preferential treatment over Common Stock.

INVESTMENT_IN_AVAILABLE_FOR_SA

INVESTMENT IN AVAILABLE FOR SALE SECURITIES	12 Months Ended
	Dec. 31, 2014
Available-For-Sale Securities [Abstract]
INVESTMENT IN AVAILABLE FOR SALE SECURITIES	Note J – INVESTMENT IN AVAILABLE FOR SALE SECURITIES
	The Company has elected the fair value option in accordance with ASC 825, Financial Instruments, as it relates to its shares held in NeoGenomics’ common stock that were acquired resulting from the NeoGenomics Master License Agreement executed on January 6, 2012. Management made the election for the fair value option related to this investment because it believes the fair value option for the NeoGenomics common stock provides a better measurement from which to compare financial statements from reporting period to reporting period. No other financial assets or liabilities are fair valued using the fair value option.
	The Company’s investment in NeoGenomics’ common stock is recorded on the accompanying balance sheets under the caption Investment in Available for Sale Securities. The carrying value of this investment on the date of acquisition approximated $1,945,000. The change in fair value from the December 31, 2013 to December 31, 2014 is an unrecognized loss of $199,894 for the remaining 86,900 shares held and is classified as other expense under the caption Unrealized Loss on Available for Sale Securities in the accompanying statements of operations. The Company classifies its investment as an available for sale security presented as a trading security on the balance sheet and the fair value is considered a Level 1 investment in the fair value hierarchy. The December 31, 2014 fair value of the investment of $362,373 is for the remaining shares held and is calculated using the closing stock price of the NeoGenomics common stock at the end of the reporting period.
	During 2014, the Company sold 113,100 shares of NeoGenomics and received proceeds in the amount of $499,820. These transactions resulted in the Company recognizing a Realized Gain on the Sale of Available for Sale Securities in the accompanying statements of operations in the amount of $338,087 in the current period.
	As of December 31, 2014, the Company held 86,900 shares of NeoGenomics stock as compared to 200,000 shares as of December 31, 2013.  The initial 1,360,000 shares were acquired in January 2012 as a result of the NeoGenomics Master License Agreement.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	Note K – SUBSEQUENT EVENTS
	None.

FINANCIAL_CONDITION_AND_GOING_

FINANCIAL CONDITION AND GOING CONCERN	12 Months Ended
	Dec. 31, 2014
Financial Condition and Going Concern [Abstract]
FINANCIAL CONDITION AND GOING CONCERN	Note L – FINANCIAL CONDITION AND GOING CONCERN
	We have prepared our financial statements on a “going concern” basis, which presumes that we will be able to realize our assets and discharge our liabilities in the normal course of business for the foreseeable future.
	Our ability to continue as a going concern is dependent upon our licensing arrangements with third parties, achieving profitable operations, obtaining additional financing and successfully bringing our technologies to the market.  The outcome of these matters cannot be predicted at this time.  Our financial statements have been prepared on a going concern basis and do not include any adjustments to the amounts and classifications of the assets and liabilities that might be necessary should we be unable to continue in business.
	If the going concern assumption was not appropriate for our financial statements then adjustments would be necessary in the carrying value of assets and liabilities, the reported expenses and the balance sheet classifications used.  Such adjustments may be material.
	At December 31, 2014 we had $7,642 cash on hand along with its NeoGenomics Stock available for sale worth $362,373. As a result, the Company estimates cash will be depleted by the fourth quarter of 2015 if no additional capital raise is undertaken.
	The Company’s plan to have sufficient cash to support operations is comprised of selling its NeoGenomics Stock, generating revenue through its relationship with NeoGenomics, providing services related to those patents, and obtaining additional equity or debt financing.
	As a result, the Company is focusing its efforts to secure funds via licensing activity or other forms of fund raising either in the debt or equity markets.  The Company has begun raising capital through the Series C Preferred Stock offering. The Company believes the Series C Preferred Stock offering, along with disciplined expense management, will allow the Company to maintain operations until the fourth quarter 2015. In addition, the Company believes the NeoGenomics relationship will provide revenue the Company in 2016. While the Company believes these efforts will create a profitable future, there is no guarantee the Company will be successful in these efforts.

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
USE OF ESTIMATES	USE OF ESTIMATES
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period.  Accordingly, actual results could differ from those estimates.  Significant estimates that are particularly susceptible to change in the near-term include the valuation of share-based compensation and consideration for services and the recoverability of the patents.
REVENUE RECOGNITION	REVENUE RECOGNITION
	Revenue is generated through the sale or license of patented technology and processes and from services provided through development agreements.  These arrangements are generally governed by contracts that dictate responsibilities and payment terms.  The Company recognizes revenues as they are earned over the duration of a license agreement or upon the sale of any owned patent once all contractual obligations have been fulfilled.  If a license agreement has an undetermined or unlimited life, the revenue is recognized over the remaining expected life of the patents. Revenue is recognized under development agreements in the period the services are performed.
CASH	CASH
	Cash and cash equivalents include cash and funds invested in money market accounts with financial institutions.
ACCOUNTS RECEIVABLE	ACCOUNTS RECEIVABLE
	Trade accounts receivable for licensing fees and development services are recorded at net contract value based upon the written agreement with the customer. In certain cases, accounts receivable may include royalties receivable from customers based upon those customers estimated sales of the products or diagnostic tests containing patented processes and technologies. The Company considers amounts past due based on the related terms of the agreement and reviews its exposure to amounts receivable based upon collection history and specific customer credit analysis.  The Company provides an allowance for doubtful amounts if collectability is no longer reasonably assured.  As of December 31, 2014 and 2013, all amounts receivable are considered fully collectable and no allowance for doubtful accounts was recorded.
EQUIPMENT	EQUIPMENT
	Equipment, which consists of office furniture, computer equipment, and leasehold improvements, are stated at cost. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which range from 3 to 10 years. Leasehold improvements are amortized using the straight-line method over the estimated useful lives of the assets or the term of the lease, whichever is shorter.
PATENTS	PATENTS
	Initial costs paid to purchase patents are capitalized and amortized using the straight line method over the remaining life of the patent. The Company capitalizes the external costs and filing fees associated with obtaining patents on its new discoveries and amortizes these costs using the straight-line method over the shorter of the legal life of the patent or its economic life, generally 17 years, beginning on the date the patent is issued.  Annual patent maintenance costs and annual license and renewal registration fees are expensed as period costs. If the applied for patents are abandoned or are not issued, the Company will expense the capitalized costs to date in the period of abandonment or earlier if abandonment appears probable.  The carrying value of patents is reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. As of December 31, 2014, the Company does not believe there has been any impairment of its patents.
INVESTMENTS	INVESTMENTS
	The Company uses the equity method to account for its equity investments in ventures for which it has 50% or less ownership and the ability to exercise significant influence over operating and financial policies, but does not control. The Company uses the cost method to account for its investments in companies that it does not control and for which it does not have the ability to exercise significant influence over operating and financial policies.
INCOME TAXES	INCOME TAXES
	The Company accounts for income taxes using the asset and liability method. Deferred tax assets and liabilities are recognized for future tax benefits and expenses or consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income for the years in which those temporary differences are expected to be recovered or settled.
	In the event the future tax consequences of differences between the financial reporting bases and tax bases of the Company’s assets and liabilities result in deferred tax assets, an evaluation is made of the probability of being able to realize the future benefits indicated by such assets is made. A valuation allowance is provided for the portion of the deferred tax asset when it is more likely than not that some portion or all of the deferred tax asset will not be realized. In assessing the probability of realizing the deferred tax assets, management considers the scheduled reversals of deferred tax liabilities, projected future taxable income, and tax planning strategies.
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION
	Stock-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the requisite service period.
	Valuation and Amortization Method – The fair value awards of stock that do not contain a market condition target are estimated on the grant date using the Black-Scholes option-pricing model. The fair value of options that contain a market condition, such as a specified hurdle price, is estimated on the grant date using a probability weighted fair value model similar to a lattice valuation model.  Both the Black-Scholes and the probability weighted valuation models require assumptions and estimates of expected volatility, expected life, expected dividend yield and expected risk-free interest rates.
	Expected Term – The expected term of the award represents the period that the Company’s stock-based awards are expected to be outstanding and was determined based on historical experience, giving consideration to the contractual terms of the stock-based awards, vesting schedules, and forfeitures due to departure prior to the end of the vesting schedule.
	Expected Volatility – Volatility is a measure of the amounts by which a financial variable such as stock price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. The Company uses the historical volatility, employing a prior period equivalent to the expected term to estimate expected volatility.
	Risk-Free Interest Rate – The Company bases the risk-free interest rate used in the Black-Scholes valuation method on the implied yield currently available on U.S. Treasury zero-coupon issues with a remaining term equivalent to the expected term of a stock award.
RESEARCH AND DEVELOPMENT EXPENSE	RESEARCH AND DEVELOPMENT EXPENSE
	The Company’s research and development costs are expensed as incurred and consist of expenses paid to consultants and external laboratories and related primarily to the costs of co-development studies, clinical trials, and projects undertaken. The R&D costs were $99,200 in 2014 and $115,934 in 2013.
FAIR VALUE OF FINANCIAL INSTRUMENTS	FAIR VALUE OF FINANCIAL INSTRUMENTS
	The Company’s financial instruments consist of cash, available for sale securities, accounts receivable, accounts payable and accrued expenses.  The Company considers the carrying values of its financial instruments in the financial statements to approximate their fair value due to the short-term nature of such items. Refer to Note J for discussion regarding the valuation of the Company’s investment in available for sale securities.
NET INCOME (LOSS) PER SHARE	NET INCOME (LOSS) PER SHARE
	Basic Earnings Per Share (“EPS”) includes no dilution and is computed by dividing income or loss available to common stockholders by the weighted average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution of securities that could share in the earnings or losses of the entity.
	Due to the net loss for the twelve-month period ended December 31, 2013, the calculation of diluted per share amounts would create an anti-dilutive result and therefore are not presented in the following table. Potentially dilutive shares at December 31, 2013, include options and warrants outstanding of 13,500,000.
	The following is an analysis of the basic and diluted earnings per common share computations for the year ended December 31, 2014:
		Year ended
		31-Dec-14
	Basic:
	Net income attributable to common stockholders	$	112,019
	Basic weighted average common shares outstanding		253,292,935
	Basic earnings per common share	$	0.0004
	Diluted:
	Net income attributable to common stockholders	$	112,019
	Basic weighted average common shares outstanding		253,292,935
	Effect of dilutive securities:
	Conversion of options and warrants		-
	Conversion of preferred shares to common shares		6,640,000
	Diluted weighted average common shares outstanding		259,932,935
	Diluted earnings per common share	$	0.0004
	During the twelve-month period ended December 31, 2014, 19,390,000 outstanding stock options and warrants were not included in the computation of diluted earnings per common share because to do so would have an antidilutive effect. Please refer to Note H regarding detail for outstanding stock options.
CONCENTRATIONS OF CREDIT RISK	CONCENTRATIONS OF CREDIT RISK
	The Company maintains its cash balances at financial institutions that are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000 per account.  From time-to-time, the Company’s cash balances exceed the amount insured by the FDIC.  Management believes the risk of loss of cash balances in excess of the insured limit to be low.
RECENT ACCOUNTING PRONOUNCEMENTS	RECENT ACCOUNTING PRONOUNCEMENTS
	In February 2013, the FASB issued an amendment, which requires disclosure of amounts reclassified out of accumulated other comprehensive income by component. In addition, an entity is required to present either on the face of the statement of operations or in the notes, significant amounts reclassified out of accumulated other comprehensive income by the respective line items of net income but only if the amount reclassified is required to be reclassified to net income in its entirety in the same reporting period. For amounts not reclassified in their entirety to net income, an entity is required to cross-reference to other disclosures that provide additional detail about those amounts. This guidance is effective prospectively for annual and interim periods beginning after December 15, 2012. The adoption of this guidance did not have a material impact on our financial results.

SUMMARY_OF_SIGNIFICANT_ACCOUNT2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Schedule of basic and diluted earnings per common share
		Year ended
		31-Dec-14
	Basic:
	Net income attributable to common stockholders	$	112,019
	Basic weighted average common shares outstanding		253,292,935
	Basic earnings per common share	$	0.0004
	Diluted:
	Net income attributable to common stockholders	$	112,019
	Basic weighted average common shares outstanding		253,292,935
	Effect of dilutive securities:
	Conversion of options and warrants		-
	Conversion of preferred shares to common shares		6,640,000
	Diluted weighted average common shares outstanding		259,932,935
	Diluted earnings per common share	$	0.0004

DEFERRED_REVENUE_Tables

DEFERRED REVENUE (Tables)	12 Months Ended
	Dec. 31, 2014
Deferred Revenue Disclosure [Abstract]
Schedule of expected future annual recognition of revenue	2015	$	43,388
	2016		43,388
	2017		43,388
	2018		43,388
	2019		18,076
	Total expected future annual amortization	$	191,628

PATENTS_Tables

PATENTS (Tables)	12 Months Ended
	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of cost and accumulated amortization		2014			2013
	Cost of Patents	$	3,985,794		$	3,985,794
	Accumulated Amortization		(2,782,009	)		(2,519,290	)
	Patents, Net of Amortization	$	1,203,785		$	1,466,504

INCOME_TAXES_Tables

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Schedule of deferred tax assets and liabilities		2014			2013
	Deferred tax assets:
	Net operating losses	$	7,877,660		$	7,682,814
	Deferred revenue		65,154			413,649
	Charitable contributions		-			510
	Depreciation and amortization		-			-
	Stock compensation		55,991			54,655
	Deferred tax asset		7,998,805			8,151,628
	Deferred tax liabilities:
	Depreciation and amortization		(4,007	)		(4,007	)
	Unrealized gain		(80,956	)		(148,920	)
	Deferred tax liability		(84,963	)		(152,927	)
	Net deferred tax asset		7,913,842			7,998,701
	Less valuation allowance		(7,913,842	)		(7,998,701	)
	Net deferred taxes	$	-		$	-
Schedule of income tax expense (Benefit)		2014			2013
	Total expense (benefit) computed by:
	Applying the U.S. Federal statutory rate		(34	)%		(34	)%
	State income taxes, net of federal tax benefit		(3	)%		(3	)%
	Valuation allowance		37	%		37	%
	Effective tax rate		-			-

STOCK_COMPENSATION_AND_EQUITY_1

STOCK COMPENSATION AND EQUITY BASED PAYMENTS (Tables)	12 Months Ended
	Dec. 31, 2014
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]
Schedule of stock option and warrant information of the company	Number of Warrants and Options Issued	2014			Weighted Average		2013			Weighted Average
					Exercise Price					Exercise Price
	Outstanding beginning of year		13,500,000		$	0.05		12,250,000		$	0.1
	Granted		6,640,000		$	0.03		17,750,000		$	0.04
	Exercised		-		$	-		-		$	-
	Forfeited		-		$	-		(8,500,000	)	$	0.12
	Expired un-exercised		(750,000	)	$	0.08		(8,000,000	)	$	0.08
	Outstanding end of the year		19,390,000		$	0.034		13,500,000		$	0.05
	Exercisable December 31		13,723,335		$	0.034		4,750,000		$	0.04
Schedule of combined stock option and warrant information of the company	31-Dec-14
	Exercise Prices	Number			Weighted-		Number			Weighted
		Outstanding			Average		Exercisable			Average
					Remaining					Remaining
					Contractual					Contractual Life
					Life (years)					(years) of
										Exercisable
										Warrants
	$0.03		3,000,000			8.5		1,000,000			8.5
	$0.03		6,640,000			9.5		6,640,000			9.5
	$0.04		7,750,000			8.75		4,083,335			8.75
	$0.04		1,000,000			3		1,000,000			3
	$0.05		1,000,000			3		1,000,000			3
	Total		19,390,000					13,723,335
Schedule of stock-based compensation and expense		2014			2013
	Director and consultant option expenses	$	58,416		$	124,889
	Employee option expenses		15,350			30,855
	Total stock compensation expenses	$	73,766		$	155,744

SUMMARY_OF_SIGNIFICANT_ACCOUNT3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Basic:
Net income attributable to common stockholders	$112,019	($912,176)
Basic weighted average common shares outstanding	253,292,935
Basic earnings per common share	$0.00
Diluted:
Net income attributable to common stockholders	112,019	-912,176
Basic weighted average common shares outstanding	253,292,935
Effect of dilutive securities:
Conversion of options and warrants
Conversion of preferred shares to common shares	6,640,000
Diluted weighted average common shares outstanding	259,932,935
Diluted earnings per common share	$0.00

SUMMARY_OF_SIGNIFICANT_ACCOUNT4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Detail Textuals) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Accounting Policies [Abstract]
Estimated useful life of property and equipment	3 to 10 years
Maximum ownership in equity investments in ventures	50.00%
Research and development costs	$99,200	$115,934
Potentially dilutive shares include options and warrants outstanding		13,500,000
Outstanding stock options and warrants not included in computation of diluted earnings per common share	19,390,000
Cash balances at financial institutions that are insured by the Federal Deposit Insurance Corporation per account	$250,000

SUMMARY_OF_SIGNIFICANT_ACCOUNT5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Detail Textuals 1) (Patents)	12 Months Ended
	Dec. 31, 2014
Patents
Finite-Lived Intangible Assets [Line Items]
Useful life of finite-lived intangible assets	17 years

DEFERRED_REVENUE_Expected_futu

DEFERRED REVENUE - Expected future annual recognition of revenue (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
Deferred Revenue Disclosure [Abstract]
2015	$43,388
2016	43,388
2017	43,388
2018	43,388
2019	18,076
Total expected future annual amortization	$191,628

DEFERRED_REVENUE_Detail_Textua

DEFERRED REVENUE (Detail Textuals) (USD $)	1 Months Ended	12 Months Ended
	Jan. 31, 2012	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Total unearned revenue		191,628
NeoGenomics Master License Agreement
Finite-Lived Intangible Assets [Line Items]
Deferred revenue received in cash	2,944,800
Period to recognize deferred revenue as income	3 years
Deferred revenue recorded and recognized as income	$2,944,800
Underlying Patents
Finite-Lived Intangible Assets [Line Items]
Estimated remaining term of the underlying patents		4 years 6 months
Underlying Patents | Minimum | NeoGenomics Master License Agreement
Finite-Lived Intangible Assets [Line Items]
Estimated remaining term of the underlying patents		1 year
Underlying Patents | Maximum | NeoGenomics Master License Agreement
Finite-Lived Intangible Assets [Line Items]
Estimated remaining term of the underlying patents		7 years

PATENTS_Details

PATENTS (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]
Cost of Patents	$3,985,794	$3,985,794
Accumulated Amortization	-2,782,009	-2,519,290
Patents, Net of Amortization	$1,203,785	$1,466,504

PATENTS_Detail_Textuals

PATENTS (Detail Textuals) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]
Amortization charged to operations	$262,719	$262,719
Patents
Finite-Lived Intangible Assets [Line Items]
Amortization charged to operations	262,719	262,719
Estimated future amortization expense year 1	260,603
Estimated future amortization expense year 2	260,603
Estimated future amortization expense year 3	260,603
Estimated future amortization expense year 4	$260,603
Weighted average remaining amortization period	4 years 6 months

INVESTMENT_Detail_Textuals_1

INVESTMENT (Detail Textuals 1) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Mar. 27, 2007	Aug. 31, 2008	Dec. 31, 2010
Schedule of Equity Method Investments [Line Items]
Percentage of membership interest	50.00%
SVM Capital LLC
Schedule of Equity Method Investments [Line Items]
Percentage of membership interest			45.00%
Carrying value of investment	0	$0
Amount of initial investment			5,000
Smart Personalized Medicine, LLC
Schedule of Equity Method Investments [Line Items]
Carrying value of investment	0	$0
Smart Personalized Medicine, LLC | License Agreement
Schedule of Equity Method Investments [Line Items]
Percentage of membership interest				20.00%
Smart Personalized Medicine, LLC | Quest License and Development Agreement
Schedule of Equity Method Investments [Line Items]
Percentage of membership interest					50.00%

LICENSE_FEES_EXPENSE_LUCENT_AG1

LICENSE FEES EXPENSE - LUCENT AGREEMENT (Detail Textuals) (Patent License Agreement, Lucent Technologies GRL Corporation, USD $)	1 Months Ended	12 Months Ended
	Sep. 26, 2004	Dec. 31, 2014	Dec. 31, 2013
Patent License Agreement | Lucent Technologies GRL Corporation
Agreement [Line Items]
Description of condition for royalty payment		The Company agreed to pay royalty fees to Lucent in the amount of the greater of an annual fee of $10,000 or at the rate of five percent (5%) on each licensed product which is sold, leased, or put into use by the Company, until cumulative royalties equal $40,000 and at the rate of one percent (1%) subsequently.
Royalty, annual fee	$10,000
Annual fee rate	5.00%
Cumulative royalties	40,000
Cumulative royalties rate	1.00%
Royalty fees paid		$6,095	$10,536

INCOME_TAXES_Details

INCOME TAXES (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Deferred tax assets:
Net operating losses	$7,877,660	$7,682,814
Deferred revenue	65,154	413,649
Charitable contributions		510
Depreciation and amortization
Stock compensation	55,991	54,655
Deferred tax asset	7,998,805	8,151,628
Deferred tax liabilities:
Depreciation and amortization	-4,007	-4,007
Unrealized gain	-80,956	-148,920
Deferred tax liability	-84,963	-152,927
Net deferred tax asset	7,913,842	7,998,701
Less valuation allowance	-7,913,842	-7,998,701
Net deferred taxes

INCOME_TAXES_Details_1

INCOME TAXES (Details 1)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Applying the U.S. Federal statutory rate	-34.00%	-34.00%
State income taxes, net of federal tax benefit	-3.00%	-3.00%
Valuation allowance	37.00%	37.00%
Effective tax rate

INCOME_TAXES_Details_Textuals

INCOME TAXES (Details Textuals) (USD $)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Decrease in the valuation allowance	$84,859
Net operating loss carry-forwards	$23,200,000

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Detail Textuals) (USD $)	12 Months Ended		1 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Jul. 31, 2013	Feb. 23, 2015
	sqft
Loss Contingencies [Line Items]
Area of office space given on lease	350
Base rent per month	$600
Settlement expense		50,000
Settlement agreement | Stephen Barnhill
Loss Contingencies [Line Items]
Amount paid for benefit of Mr. Barnhilland under settlement agreement			50,000
Containing Consent Order | Federal Trade Commission (FTC) | Subsequent Event
Loss Contingencies [Line Items]
Settlement expense				$17,963

STOCK_COMPENSATION_AND_EQUITY_2

STOCK COMPENSATION AND EQUITY BASED PAYMENTS (Details) (Warrants and Options, USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Warrants and Options
Number of Warrants and Options Issued
Outstanding beginning of year	13,500,000	12,250,000
Granted	6,640,000	17,750,000
Exercised
Forfeited		-8,500,000
Expired un-exercised	-750,000	-8,000,000
Outstanding end of the year	19,390,000	13,500,000
Exercisable December 31	13,723,335	4,750,000
Weighted Average Exercise Price
Outstanding beginning of year	$0.05	$0.10
Granted	$0.03	$0.04
Exercised
Forfeited		$0.12
Expired un-exercised	$0.08	$0.08
Outstanding end of the year	$0.03	$0.05
Exercisable December 31	$0.03	$0.04

STOCK_COMPENSATION_AND_EQUITY_3

STOCK COMPENSATION AND EQUITY BASED PAYMENTS (Details 1) (Stock Options and Warrants, USD $)	12 Months Ended
	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number Outstanding	19,390,000
Number Exercisable	13,723,335
$0.03
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Prices	$0.03
Number Outstanding	3,000,000
Weighted-Average Remaining Contractual Life (years)	8 years 6 months
Number Exercisable	1,000,000
Weighted Average Remaining Contractual Life (years) of Exercisable Warrants and Options	8 years 6 months
$0.03
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Prices	$0.03
Number Outstanding	6,640,000
Weighted-Average Remaining Contractual Life (years)	9 years 6 months
Number Exercisable	6,640,000
Weighted Average Remaining Contractual Life (years) of Exercisable Warrants and Options	9 years 6 months
$0.04
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Prices	$0.04
Number Outstanding	7,750,000
Weighted-Average Remaining Contractual Life (years)	8 years 9 months
Number Exercisable	4,083,335
Weighted Average Remaining Contractual Life (years) of Exercisable Warrants and Options	8 years 9 months
$0.04
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Prices	$0.04
Number Outstanding	1,000,000
Weighted-Average Remaining Contractual Life (years)	3 years
Number Exercisable	1,000,000
Weighted Average Remaining Contractual Life (years) of Exercisable Warrants and Options	3 years
$0.05
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Prices	$0.05
Number Outstanding	1,000,000
Weighted-Average Remaining Contractual Life (years)	3 years
Number Exercisable	1,000,000
Weighted Average Remaining Contractual Life (years) of Exercisable Warrants and Options	3 years

STOCK_COMPENSATION_AND_EQUITY_4

STOCK COMPENSATION AND EQUITY BASED PAYMENTS (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]
Director and consultant option expenses	$58,416	$124,889
Employee option expenses	15,350	30,855
Total stock compensation expenses	$73,766	$155,744

STOCK_COMPENSATION_AND_EQUITY_5

STOCK COMPENSATION AND EQUITY BASED PAYMENTS (Detail Textuals) (USD $)	12 Months Ended
	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based expense included in net income	$73,766
Director option expenses	33,199
Stock option expenses related to employees and consultants	40,567
Stock Options and Warrants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation unrecognized for stock options and warrants	120,175
Average remaining vesting period for recognition of unrecognized expenses related to stock options and warrants	1 year 6 months
Weighted average remaining life of outstanding warrants and options	8 years 6 months
Aggregate intrinsic value of outstanding and exercisable options and warrants outstanding and exercisable	0
Closing price of outstanding and exercisable options and warrants less exercise prices	$0.02

STOCK_COMPENSATION_AND_EQUITY_6

STOCK COMPENSATION AND EQUITY BASED PAYMENTS (Detail Textuals 1) (Stock Options, USD $)	1 Months Ended
	Jul. 25, 2013	Oct. 21, 2013
Henry Kaplan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option granted	1,500,000
Kevin Kowbel
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option granted	1,500,000
Eric Winger
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option granted	1,500,000
Messrs Kaplan And Winger
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option vest or to be vested	250,000
Exercise price of each option granted (in dollars per share)	0.027
Method used for fair value assumptions	Black-Scholes pricing model
Fair value of each stock option (in dollars per share)	0.02
Dividend yield	0.00%
Risk free interest rate	1.91%
Expected life of option	5 years
Expected volatility rate	98.00%
Aggregate value of stock options	60,124
Vesting period of option	3 years
William F Quirk
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option granted		1,500,000
Number of option vest or to be vested		250,000
Exercise price of each option granted (in dollars per share)		$0.04
Vesting period of option		6 months

STOCK_COMPENSATION_AND_EQUITY_7

STOCK COMPENSATION AND EQUITY BASED PAYMENTS (Detail Textuals 2) (Stock Options, USD $)	1 Months Ended
	Oct. 21, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Compensation cost not yet recognized	$203,931
Options Compensation cost recognition period	3 years
Employees And Consultants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option granted to purchase common stock	6,000,000
Vesting period of option	3 years
Exercise price of option	$0.04
Expiry date of option	31-Oct-23
Mark A. Moore
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option granted to purchase common stock	1,000,000
Hong Zhang
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option granted to purchase common stock	750,000

STOCKHOLDERS_EQUITY_Detail_Tex

STOCKHOLDERS' EQUITY (Detail Textuals) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2009	Dec. 31, 2013	Mar. 31, 2009
Class of Stock [Line Items]
Dividend accrued on Series B preferred stock	$373,346		$308,724
Series B Preferred Stock
Class of Stock [Line Items]
Series B Preferred Stock, shares authorized (in shares)	20,625,000	20,625,000	20,625,000	13,750,000
Number of series B preferred stock issued (in shares)		19,402,675
Amount of Series B Preferred Stock Issued		1,490,015
Dividend rate on Series B Preferred Stock	10.00%
Dividend accrued on Series B preferred stock	373,346		308,724
Accrued dividend on common stock	$0.05

STOCKHOLDERS_EQUITY_Detail_Tex1

STOCKHOLDERS' EQUITY (Detail Textuals 1) (Series C Preferred Stock, USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Series C Preferred Stock
Class Of Stock [Line Items]
Preferred Stock, shares issued	6,640,000	2,000,000
Value of preferred shares issued	$332,000	$160,000
Preferred shares warrant feature per share	$0.03
Preferred shares contingency warrant feature per share	$0.03
Series C Preferred stock, contingency warrant exercise description	The contingency warrants will be issued only if the company has not attained profitability by the end of the first quarter 2016. The holders must exercise fifty percent of the warrants if the market price for the Company's common stock is $0.20 for a period of thirty consecutive calendar days. The holders must also exercise fifty percent of the warrants if the market price for the Company's common stock is $0.30 for a period of thirty consecutive calendar days.
Percentage of warrants exercise if market price for Company's common stock is $0.20	50.00%
Price per share for exercise of warrants, condition one	$0.20
Number of days for common stock price at $0.20	30 days
Percentage of warrants exercise if market price for Company's common stock is $0.30	50.00%
Price per share for exercise of warrants, condition two	0.3
Number of days for common stock price at $0.30	30 days
Valuation method for warrants	Black Scholes Method
Fair value of exercise price of warrants	$0.03

INVESTMENT_IN_AVAILABLE_FOR_SA1

INVESTMENT IN AVAILABLE FOR SALE SECURITIES (Detail Textuals) (USD $)	1 Months Ended	12 Months Ended
	Jan. 31, 2012	Dec. 31, 2014	Dec. 31, 2013
Schedule of Available-for-sale Securities [Line Items]
Number of shares sold during third and fourth quarters of 2012		261,384,810	252,557,310
Neo Genomics Laboratories Inc
Schedule of Available-for-sale Securities [Line Items]
Unrecognized loss on available for sale securities		$199,894
Number of remaining shares held		86,900
Number of shares sold during third and fourth quarters of 2012		113,100
Amount of shares sold during third and fourth quarters of 2012		499,820
Realized gain on sale of available for sale securities		338,087
Number of shares of Neo Genomics stock held		86,900	200,000
Number of shares initially acquired	1,360,000
Carrying value | Neo Genomics Laboratories Inc
Schedule of Available-for-sale Securities [Line Items]
Available for sale securities		1,945,000
Fair value | Neo Genomics Laboratories Inc
Schedule of Available-for-sale Securities [Line Items]
Available for sale securities		$362,373

FINANCIAL_CONDITION_AND_GOING_1

FINANCIAL CONDITION AND GOING CONCERN (Detail Textuals) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Financial Condition and Going Concern [Abstract]
Cash	$7,642	$71,991	$171,424
Investment in NeoGenomics Stock available for sale	$362,373	$724,000